Marinus Pharmaceuticals Inc
(FRA:61Y)
€
0.302
0.002 (0.67%)
Market Cap: 17.09 Mil
Enterprise Value: 30.25 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 37/100 Marinus Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 16, 2023 / 02:00PM GMT
Release Date Price:
€7.75
(-2.52%)
Brian Abrahams
RBC Capital Markets - Analyst
So thanks, everybody, for joining us. I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next featured company is Marinus Pharmaceuticals. From Marinus, we have their Chief Scientific Officer, Alex Aimetti, and their Chief Financial Officer, Steve Pfanstiel. Alex and Steve, thanks so much for joining us.
Alex Aimetti
Marinus Pharmaceuticals, Inc. - Chief Scientific Officer
Yeah, thanks for having us.
Steve Pfanstiel
Marinus Pharmaceuticals, Inc. - CFO & COO
Yeah, morning. Thanks for having us.
Questions & Answers
Brian Abrahams
RBC Capital Markets - Analyst
Great. So, there's a lot to cover. So, let's kick things off. Maybe starting -- we'll start on the commercial side of things. Aimetti, tell me -- can you talk to us -- you just reported good sales and continued growth of the drug.
Tell us how the launch is progressing now with two full quarters of sales
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot